U.S. Markets closed
  • S&P Futures

    3,825.50
    +36.00 (+0.94%)
     
  • Dow Futures

    31,045.00
    +264.00 (+0.85%)
     
  • Nasdaq Futures

    11,610.50
    +81.00 (+0.70%)
     
  • Russell 2000 Futures

    1,727.60
    +19.60 (+1.13%)
     
  • Crude Oil

    108.46
    +2.70 (+2.49%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.59%)
     
  • EUR/USD

    1.0430
    +0.0003 (+0.0313%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2094
    -0.0009 (-0.0750%)
     
  • USD/JPY

    135.0910
    -0.0840 (-0.0621%)
     
  • BTC-USD

    19,188.90
    -24.49 (-0.13%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    26,095.32
    +159.70 (+0.62%)
     

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences in June:

  • Jefferies Healthcare Conference: Fireside chat on Thursday, June 9, 2022 at 4:30 p.m. ET.

  • Goldman Sachs 43rd Annual Global Healthcare Conference: Fireside chat on Wednesday, June 15, 2022 at 9:20 a.m. PT.

The conference events will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. Replays of the webcasts will be available for 90 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178